Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
Open Access
- 4 August 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (18) , e025198
Abstract
Background: Venous thromboembolism (VTE) contributes significantly to COVID‐19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen activator receptor (suPAR) reflect hyperinflammation and are strongly predictive of outcomes in COVID‐19. Whether suPAR levels identify patients with COVID‐19 at risk for VTE is unclear. Methods and Results: We leveraged a multinational observational study of patients hospitalized for COVID‐19 with suPAR and D‐dimer levels measured on admission. In 1960 patients (mean age, 58 years; 57% men; 20% Black race), we assessed the association between suPAR and incident VTE (defined as pulmonary embolism or deep vein thrombosis) using logistic regression and Fine‐Gray modeling, accounting for the competing risk of death. VTE occurred in 163 (8%) patients and was associated with higher suPAR and D‐dimer levels. There was a positive association between suPAR and D‐dimer (β=7.34; P =0.002). Adjusted for clinical covariables, including D‐dimer, the odds of VTE were 168% higher comparing the third with first suPAR tertiles (adjusted odds ratio, 2.68 [95% CI, 1.51–4.75]; P <0.001). Findings were consistent when stratified by D‐dimer levels and in survival analysis accounting for death as a competing risk. On the basis of predicted probabilities from random forest, a decision tree found the combined D‐dimer <1 mg/L and suPAR <11 ng/mL cutoffs, identifying 41% of patients with only 3.6% VTE probability. Conclusions: Higher suPAR was associated with incident VTE independently of D‐dimer in patients hospitalized for COVID‐19. Combining suPAR and D‐dimer identified patients at low VTE risk. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04818866.Keywords
This publication has 37 references indexed in Scilit:
- A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney diseaseNature Medicine, 2017
- Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney diseaseNature Medicine, 2016
- Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolismThrombosis and Haemostasis, 2016
- Soluble Urokinase Receptor and Chronic Kidney DiseaseNew England Journal of Medicine, 2015
- suPAR: A New Biomarker for Cardiovascular Disease?Canadian Journal of Cardiology, 2015
- Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse EventsJournal of the American Heart Association, 2014
- The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and CoagulationCurrent Pharmaceutical Design, 2011
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009
- Unbiased Recursive Partitioning: A Conditional Inference FrameworkJournal of Computational and Graphical Statistics, 2006
- Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric ApproachBiometrics, 1988